MannKind Corp. (MNKD)

[Denise Chanterelle]

Anphastar Presentation Sept 2015

Recombinant Human Insulin (RHI)
- Signed supply agreement with MannKind to supply RHI for Afrezza®
- Agreement specifies minimum annual sales of 24 million euros annually for 5 years from 2015 - 2019
- Further amounts may be purchased
- Several other customers currently purchasing R&D quantities for filings outside of the US
- One customer buying production quantities outside of the US
- Signed Option Agreement to supply additional quantities in 2016-2019
- If MannKind chooses not to exercise its option, they pay a cancelation fee

IMO, Sanofi must be planning for international expansion by supplying insulin for Afrezza on top of Amphastar's insulin.

MannKind has bigger ambition for its Technosphere technology. Aloha.